248 related articles for article (PubMed ID: 20406839)
1. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.
Wang S; Ren W; Liu J; Lahat G; Torres K; Lopez G; Lazar AJ; Hayes-Jordan A; Liu K; Bankson J; Hazle JD; Lev D
Clin Cancer Res; 2010 May; 16(9):2591-604. PubMed ID: 20406839
[TBL] [Abstract][Full Text] [Related]
2. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
Oh Y; Swierczewska M; Kim TH; Lim SM; Eom HN; Park JH; Na DH; Kim K; Lee KC; Pomper MG; Lee S
J Control Release; 2015 Dec; 220(Pt B):671-81. PubMed ID: 26381901
[TBL] [Abstract][Full Text] [Related]
3. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines.
Tomek S; Koestler W; Horak P; Grunt T; Brodowicz T; Pribill I; Halaschek J; Haller G; Wiltschke C; Zielinski CC; Krainer M
Eur J Cancer; 2003 Jun; 39(9):1318-29. PubMed ID: 12763223
[TBL] [Abstract][Full Text] [Related]
4. Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.
Ren W; Korchin B; Lahat G; Wei C; Bolshakov S; Nguyen T; Merritt W; Dicker A; Lazar A; Sood A; Pollock RE; Lev D
Clin Cancer Res; 2008 Sep; 14(17):5466-75. PubMed ID: 18765538
[TBL] [Abstract][Full Text] [Related]
5. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
6. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.
Lopez G; Liu J; Ren W; Wei W; Wang S; Lahat G; Zhu QS; Bornmann WG; McConkey DJ; Pollock RE; Lev DC
Clin Cancer Res; 2009 May; 15(10):3472-83. PubMed ID: 19417021
[TBL] [Abstract][Full Text] [Related]
7. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
[TBL] [Abstract][Full Text] [Related]
8. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
[TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
10. Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma.
Karlisch C; Harati K; Chromik AM; Bulut D; Klein-Hitpass L; Goertz O; Hirsch T; Lehnhardt M; Uhl W; Daigeler A
Int J Oncol; 2013 Mar; 42(3):945-56. PubMed ID: 23338823
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.
Pasello G; Urso L; Silic-Benussi M; Schiavon M; Cavallari I; Marulli G; Nannini N; Rea F; Ciminale V; Favaretto A
J Thorac Oncol; 2014 Jul; 9(7):1008-1017. PubMed ID: 24922007
[TBL] [Abstract][Full Text] [Related]
12. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
13. Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.
Giacomini A; Righi M; Cleris L; Locatelli SL; Mitola S; Daidone MG; Gianni AM; Carlo-Stella C
Angiogenesis; 2013 Jul; 16(3):707-22. PubMed ID: 23605004
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
Ren W; Korchin B; Zhu QS; Wei C; Dicker A; Heymach J; Lazar A; Pollock RE; Lev D
Clin Cancer Res; 2008 May; 14(9):2785-95. PubMed ID: 18451246
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis.
Shankar S; Ganapathy S; Srivastava RK
Clin Cancer Res; 2008 Nov; 14(21):6855-66. PubMed ID: 18980980
[TBL] [Abstract][Full Text] [Related]
17. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
18. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
19. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
20. Andrographolide sensitizes prostate cancer cells to TRAIL-induced apoptosis.
Wei RJ; Zhang XS; He DL
Asian J Androl; 2018; 20(2):200-204. PubMed ID: 28869219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
